Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand

Clinical and Vaccine Immunology

Volumn 19, Issue 8, 2012, Pages 1119-1125

  Wang, Bao Zhong ^a   Gill, Harvinder S ^a,b   Kang, Sang Moo ^a,c   Wang, Li ^a   Wang, Ying Chun ^a   Vassilieva, Elena V ^a   Compans, Richard W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Electrical and Computer Engineering   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX PROTEIN; MATRIX PROTEIN 2; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RESISTANCE; INFLUENZA; INFLUENZA VACCINATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS LIKE AGENT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; FLAGELLIN; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, MUCOSAL; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; LIGANDS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 5; VACCINES, VIROSOME; VIRAL MATRIX PROTEINS;

EID: 84864546404     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00153-12     Document Type: Article

References (44)

1. Acharya R, et al. 2010. Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 107:15075-15080.
2. Andersen-Nissen E, et al. 2005. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc. Natl. Acad. Sci. U. S. A. 102:9247-9252. (Pubitemid 40923549)
3. Ben-Yedidia T, Arnon R. 1998. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 64:9-15. (Pubitemid 29029873)
4. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. 1993. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 74(Pt 1):143-146. (Pubitemid 23053779)
5. Brandtzaeg P. 2003. Role of mucosal immunity in influenza. Dev. Biol. (Basel) 115:39-48.
6. Carrat F, Flahault A. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852- 6862.
7. Chen BJ, Leser GP, Morita E, Lamb RA. 2007. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J. Virol. 81:7111-7123. (Pubitemid 46986647)
8. De Filette M, et al. 2008. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J. Biol. Chem. 283:11382-11387.
9. De Filette M, et al. 2005. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337:149-161. (Pubitemid 40725448)
10. Denis J, et al. 2008. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26:3395-3403.
11. Eliasson DG, et al. 2008. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 26:1243-1252.
12. Fan J, et al. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993-3003. (Pubitemid 39037199)
13. Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. 1998. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. U. S. A. 95:9477-9481. (Pubitemid 28506256)
14. Gerhard W, Mozdzanowska K, Zharikova D. 2006. Prospects for universal influenza virus vaccine. Emerg. Infect. Dis. 12:569-574.
15. Hughey PG, et al. 1995. Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. Virology 212:411-421.
16. Huleatt JW, et al. 2008. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201-214. (Pubitemid 50008089)
17. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172:5598-5605. (Pubitemid 38542062)
18. Le Moigne V, Robreau G, Mahana W. 2008. Flagellin as a good carrier and potent adjuvant for Th1 response: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen. Mol. Immunol. 45:2499-2507.
19. Liang B, Hyland L, Hou S. 2001. Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J. Virol. 75:5416-5420. (Pubitemid 32448568)
20. Liu W, Chen YH. 2005. High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur. J. Immunol. 35:505-514. (Pubitemid 40331328)
21. Liu W, et al. 2004. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 23:366-371. (Pubitemid 39463056)
22. McQuiston JR, et al. 2004. Sequencing and comparative analysis of flagellin genes fliC, fljB, and flpA from Salmonella. J. Clin. Microbiol. 42:1923-1932. (Pubitemid 38637803)
23. Meltzer MI, Bridges CB. 2003. Economic analysis of influenza vaccination and treatment. Ann. Intern. Med. 138:608-609.
24. Mizel SB, et al. 2009. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin. Vaccine Immunol. 16:21-28.
25. Mozdzanowska K, et al. 2003. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21:2616-2626. (Pubitemid 36561354)
26. Neirynck S, et al. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1157-1163. (Pubitemid 29474420)
27. Nempont C, et al. 2008. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J. Immunol. 181:2036-2043.
28. Quan FS, Huang C, Compans RW, Kang SM. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81:3514-3524. (Pubitemid 46456660)
29. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
30. Schotsaert M, De Filette M, Fiers W, Saelens X. 2009. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 8:499-508.
31. Schultz-Cherry S, et al. 2000. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278:55-59. (Pubitemid 32002594)
32. Schwartz B, et al. 2006. Universal influenza vaccination in the United States: are we ready? Report of a meeting. J. Infect. Dis. 194(Suppl. 2): S147-S154. (Pubitemid 44630959)
33. Silverman M, Zieg J, Hilmen M, Simon M. 1979. Phase variation in Salmonella: genetic analysis of a recombinational switch. Proc. Natl. Acad. Sci. U. S. A. 76:391-395. (Pubitemid 9110202)
34. Skountzou I, et al. 2010. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28:4103-4112.
35. Smith KD, et al. 2003. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 4:1247-1253. (Pubitemid 37540694)
36. Song JM, Van Rooijen N, Bozja J, Compans RW, Kang SM. 2011. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 108:757-761.
37. Song JM, et al. 2011. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6:e14538. doi:10.1371/journal.pone. 0014538.
38. Talbot HK, et al. 2010. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 5:e14442. doi:10.1371/journal.pone.0014442.
39. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. 1990. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64:1375-1377. (Pubitemid 20087784)
40. Wang BZ, et al. 2008. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 82:11813-11823.
41. Wang BZ, et al. 2010. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One 5:e13972. doi:10.1371/journal.pone.0013972.
42. Zebedee SL, Lamb RA. 1988. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 62:2762-2772.
43. Zieg J, Silverman M, Hilmen M, Simon M. 1977. Recombinational switch for gene expression. Science 196:170-172. (Pubitemid 8067679)
44. Zimmermann R, Mollay C. 1986. Import of honeybee prepromelittin into the endoplasmic reticulum. Requirements for membrane insertion, processing, and sequestration. J. Biol. Chem. 261:12889-12895. (Pubitemid 17204256)